Drugs / BD111
BD111
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06474416 | Sep 2023 → Oct 2025 overdue | herpes simplex virus keratitis | Shanghai BDgene Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06474442 | Apr 2025 → Dec 2026 expected | stromal keratitis | Shanghai BDgene Co., Ltd. | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04560790 | Nov 2020 → Jul 2022 | blindness (disorder), herpes simplex infectious disease, keratitis | Shanghai BDgene Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BD111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04560790 ↗ |
| Known as | BD111 Lentivirus-like particles | “BD111 Lentivirus-like particles” NCT06474416 ↗ |
| Known as | BD111 Lentivirus-like particles, also called HSV-1-erasing lentiviral particles (HELP) | “BD111 Lentivirus-like particles, also called HSV-1-erasing lentiviral particles (HELP)” NCT06474442 ↗ |
| Modality | CRISPR / gene editing | “CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy” NCT04560790 ↗ |
| Route | Other | “administered via corneal injection” NCT04560790 ↗ |